Top 90+ Pharmaceutical Companies In San Diego In 2021
← Visit blog

Top 90+ Pharmaceutical Companies In San Diego In 2021

Updated on March 11th, 2021

Top 90+ Pharmaceutical Companies In San Diego In 2021

A hand curated list of 90+ top pharmaceutical companies in San Diego.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Elevation Pharmaceuticals ($10M to $50M)
  2. Apricus Biosciences ($50M to $100M)
  3. Omniome ($10M to $50M)
  4. Aragon Pharmaceuticals ($10M to $50M)
  5. Plexium ($1M to $10M)
  6. Innovus Pharmaceuticals ($1M to $10M)
  7. Neurolixis (Less than $1M)
  8. Ceregene ($10M to $50M)
  9. Epirium Bio ($10M to $50M)
  10. Denovo Biopharma ($1M to $10M)
  11. ADARx Pharmaceuticals (Less than $1M)
  12. Novoron Bioscience (Less than $1M)
  13. Amplyx Pharmaceuticals ($10M to $50M)
  14. Skye Bioscience ($1M to $10M)
  15. Inception Sciences ($10M to $50M)
  16. Decipher Biosciences (Less than $1M)
  17. Rempex Pharmaceuticals ($1M to $10M)
  18. iTherX ($10M to $50M)
  19. Histogen ($1M to $10M)
  20. Tocagen (Less than $1M)
  21. Aristea Therapeutics (Less than $1M)
  22. Evofem Biosciences ($1M to $10M)
  23. Arena Pharmaceuticals ($10M to $50M)
  24. Abwiz Bio (Less than $1M)
  25. Viriom ($10M to $50M)
  26. Neuropore Therapies ($1M to $10M)
  27. BioIntervene ($1M to $10M)
  28. Sorrento Therapeutics ($10M to $50M)
  29. Biosortia Pharmaceuticals ($1M to $10M)
  30. ACADIA Pharmaceuticals ($50M to $100M)
  31. Adamis Pharmaceuticals ($1M to $10M)
  32. BioBlocks ($50M to $100M)
  33. Nanome (Less than $1M)
  34. Escient Pharmaceuticals ($1M to $10M)
  35. Prometheus Biosciences ($10M to $50M)
  36. Kinnate Biopharma (Less than $1M)
  37. Sorrento Therapeutics ($1M to $10M)
  38. Allylix ($10M to $50M)
  39. Peptide Logic (Less than $1M)
  40. Lumena Pharmaceuticals ($10M to $50M)
  41. PROTEIN LOUNGE (Less than $1M)
  42. Zogenix (Less than $1M)
  43. aTyr Pharma ($10M to $50M)
  44. Ambra BioScience LLC - Lovidia (Less than $1M)
  45. Genoa Pharmaceuticals ($1M to $10M)
  46. Zavante Therapeutics ($10M to $50M)
  47. Mirum Pharmaceuticals ($50M to $100M)
  48. PharmAkea Therapeutics ($1M to $10M)
  49. Mast Therapeutics (Less than $1M)
  50. ReVision Therapeutics (Less than $1M)
  51. Ligand Pharmaceuticals ($10M to $50M)
  52. Longboard Pharmaceuticals ($10M to $50M)
  53. HUYA Bioscience ($1M to $10M)
  54. Engrail Therapeutics ($10M to $50M)
  55. Dauntless Pharmaceuticals ($1M to $10M)
  56. Sevion Therapeutics ($50M to $100M)
  57. Marijuana Company Of America (Less than $1M)
  58. Onchilles Pharma ($10M to $50M)
  59. Mapp Biopharmaceutical ($1M to $10M)
  60. MEI Pharma ($1M to $10M)
  61. MabVax Therapeutics ($1M to $10M)
  62. Genelux ($1M to $10M)
  63. PvP Biologics ($1M to $10M)
  64. MedImpact Healthcare Systems ($10M to $50M)
  65. Camino Pharma (Less than $1M)
  66. AnaBios ($1M to $10M)
  67. ARS Pharmaceuticals ($1M to $10M)
  68. Plex Pharmaceuticals ($1M to $10M)
  69. Otonomy (Less than $1M)
  70. Ocunexus Therapeutics ($1M to $10M)
  71. Librede (Less than $1M)
  72. Receptos ($1M to $10M)
  73. MediciNova ($1M to $10M)
  74. Jaleva Pharmaceuticals ($1M to $10M)
  75. Reneo Pharmaceuticals ($1M to $10M)
  76. Elgia Therapeutics ($10M to $50M)
  77. RayzeBio ($10M to $50M)
  78. Sonexa Therapeutics (Less than $1M)
  79. LPATH ($50M to $100M)
  80. NantKwest (Less than $1M)
  81. Ambit Biosciences ($10M to $50M)
  82. Turning Point Therapeutics ($50M to $100M)
  83. Metacrine ($10M to $50M)
  84. Tioga Pharmaceuticals (Less than $1M)
  85. Molecular Stethoscope ($1M to $10M)
  86. Cosmederm Bioscience (Less than $1M)
  87. Mirati Therapeutics (Less than $1M)
  88. Selexagen Therapeutics ($1M to $10M)
  89. Adastra Pharmaceuticals ($1M to $10M)
  90. Viracta Therapeutics ($10M to $50M)
  91. Crinetics Pharmaceuticals (Less than $1M)
  92. Neurana Pharmaceuticals ($1M to $10M)
  93. Ensysce Biosciences (Less than $1M)
  94. Ansun BioPharma ($1M to $10M)
  95. Aspen Neuroscience (Less than $1M)
  96. La jolla Pharmaceutical ($1M to $10M)
  97. Idun Pharmaceuticals ($10M to $50M)
  98. Pipeline Therapeutics ($1M to $10M)
  99. Meritage Pharma ($10M to $50M)


  1. Elevation Pharmaceuticals ($10M to $50M)

    Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients' lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders -- employees, investors, partners, and patients.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $30M raised in January, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. brown wooden table and chairs


  3. Apricus Biosciences ($50M to $100M)

    Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that has an approved product, Vitaros®, for the treatment of ED. Vitaros® is approved in Europe and Canada and will be commercialized by Apricus’ marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), and Bracco SpA. Femprox®, the Company’s product candidate for the treatment of FSAID, has successfully completed a nearly 400-subject proof-of-concept study.

    • $50M to $100M annual revenues
    • 51-100 employees
    • $10M raised in March, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. people having meeting on rectangular brown table


  5. Omniome ($10M to $50M)

    Omniome engages in developing a proprietary DNA sequencing platform capable of delivering unsurpassed sequencing accuracy. Backed by leading life sciences venture investors and a proven management team, Omniome’s vision is to be the most trusted DNA sequencing platform and leader in clinical sequencing. Founded in 2013, the company is headquartered in San Diego, California, United States.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $60M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. men using computers


  7. Aragon Pharmaceuticals ($10M to $50M)

    Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $50M raised in October, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. people using desktop computer inside office


  9. Plexium ($1M to $10M)

    Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines. The company develops ‘molecular glues’ that alter E3-ligase substrate recognition; inducing, inhibiting or modulating degradation of proteins for therapeutic benefit. It utilizes DNA-encoded libraries to search for molecular-glue degraders in high throughput cell-based assays. Plexium was founded in 2017 and is based in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $35M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. group of people sitting beside rectangular wooden table with laptops


  11. Innovus Pharmaceuticals ($1M to $10M)

    Innovus Pharma (INNV) is an emerging pharmaceutical company that develops, in-licenses, acquires, and markets prescription and consumer health products in dermatology, autoimmune, respiratory, and sexual dysfunction diseases with unique packaging and presentation for better patient compliance, convenience and results. Headquartered in San Diego, California, Innovus Pharma was founded in 2011.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.1M raised in February, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  12. man and woman sitting at table


  13. Neurolixis (Less than $1M)

    Neurolixis is a clinical-stage specialty pharmaceutical company focused on developing medicines targeting unmet disorders of the nervous system. The Company has two therapeutic candidates in clinical development: The most advanced compound, NLX-112, is a potential symptomatic treatment for dyskinesia in Parkinson’s disease (PD) ready for Phase 2 clinical studies. The Company also has NLX-101 in Phase I clinical development for Rett Syndrome, a neurodevelopmental disorder that affects roughly 16,000 children in the US and 50,000 in the industrial world.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in July, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  14. three women sitting around table using laptops


  15. Ceregene ($10M to $50M)

    Ceregene is a private, San Diego-based biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. Their clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor, which is about to enter Phase 2 studies for the treatment of Alzheimer's disease, and CERE-120, which recently completed a Phase 2 trial in Parkinson's disease and is currently being evaluated for future development. CERE-135 and CERE-140 are in preclinical development for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and ocular diseases, respectively.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $11.5M raised in November, 2010
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  16. photo of industrial machines near table


  17. Epirium Bio ($10M to $50M)

    Epirium Bio is a clinical stage biopharmaceutical company that has uncovered unique insights into the biology of mitochondrial biogenesis and function, leading to an advanced understanding of its pleotropic clinical effect in disease.These findings have led to the discovery of a novel, previously undescribed pharmacological approach to the treatment of diseases characterized by deficits in these pathways. They have identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and function. They are currently developing their lead clinical candidate, which has been shown to trigger mitochondrial biogenesis in early human studies, as a potential treatment across a number of therapeutic areas, starting with rare diseases.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $85M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  18. people sitting in front of computer monitors


  19. Denovo Biopharma ($1M to $10M)

    Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $45.8M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  20. man in gray sweatshirt sitting on chair in front of iMac


  21. ADARx Pharmaceuticals (Less than $1M)

    ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts. It discovers and develops innovative therapeutics that can utilize a family of endogenous enzymes called adenosine deaminase acting on RNA (ADAR) to precise target and correct single point mutations on an mRNA, thus the production of desired and functional protein is restored. It was founded in 2019 and is headquartered in San Diego, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $6M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  22. rectangular brown wooden table


  23. Novoron Bioscience (Less than $1M)

    Novoron Bioscience develops novel therapeutic approaches for the treatment of disorders of the central nervous system. The company has made proprietary scientific discoveries in treatment of various pathologies of the central nervous system and is advancing a pipeline of biologic therapeutics for multiple sclerosis, spinal cord injury and glaucoma. Novoron is a Delaware C-corp headquartered in San Diego, California and is part of the JLABS innovation community.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.7M raised in December, 2015
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  24. people sitting on black chairs


  25. Amplyx Pharmaceuticals ($10M to $50M)

    Amplyx Pharmaceuticals is a pre-clinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The company develops innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx Pharmaceuticals was founded in 2006 and is headquartered in San Diego, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.5M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  26. selective focus photography of desk lamp on table


  27. Skye Bioscience ($1M to $10M)

    Skye Bioscience is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids, designed to alleviate a variety of diseases and symptoms by selectively targeting CB1 and CB2 receptors. Skye Bioscience is developing a novel and proprietary class of product candidates that are designed to target the body's nervous and immune systems without inducing many of the undesirable side effects typically associated with currently available therapeutics.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $7M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  28. Inception Sciences ($10M to $50M)

    Founded in 2011, Inception Sciences is a small molecule pharmaceutical incubator. Their focus is on creating high-value therapies with transformative potential to address diseases and disorders with significant unmet needs. Through partnerships with academic experts, they are translating biological insights into highly-targeted, novel drugs. Their team has a proven track record of drug discovery, having played pivotal roles in the discovery of clinical-stage compounds for the treatment of fibrosis, asthma, and COPD at Amira Pharmaceuticals, and of several high-profile drugs at Merck.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $5M raised in June, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  29. two women sitting beside table using MacBooks


  30. Decipher Biosciences (Less than $1M)

    Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with pharmaceutical companies to identify biomarkers of response to novel therapeutics.

    • Less than $1M annual revenues
    • 11-50 employees
    • $13M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  31. rectangular brown wooden table with chair lot inside building


  32. Rempex Pharmaceuticals ($1M to $10M)

    Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

    • $1M to $10M annual revenues
    • 1001-5000 employees
    • $67.5M raised in November, 2011
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  33. grey wooden table and black leather rolling chairs


  34. iTherX ($10M to $50M)

    iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3.2M raised in November, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  35. brown and white table and chairs


  36. Histogen ($1M to $10M)

    Histogen is a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body. The company’s innovative technology platform utilizes cell-conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells, developing therapeutic products that address underserved, multi-billion US dollar global markets. It was founded in 2007 by Dr. Gail Naughton and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $14M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  37. rolling armchair beside table


  38. Tocagen (Less than $1M)

    Tocagen is a biopharmaceutical company, engages in the discovery, development, and commercialization of products for the treatment of cancer. It develops gene therapy products for treating primary tumors and metastatic diseases. The company's products comprise Prodrug Activator product candidates for treating glioblastoma multiforme; and immunotherapeutic product candidates for treating metastatic malignant melanoma. Tocagen was founded in 2007 and is based in San Diego, California.

    • Less than $1M annual revenues
    • 101-250 employees
    • $72.5M raised in April, 2017
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  39. men sitting of chair inside room


  40. Aristea Therapeutics (Less than $1M)

    Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.The company's therapies include developing drugs, enabling inflammatory diseases patients to address their unmet medical needs.

    • Less than $1M annual revenues
    • 1-10 employees
    • $39.6M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  41. people sitting and using laptops


  42. Evofem Biosciences ($1M to $10M)

    Lithera is developing products for aesthetic medicine to address both medical and lifestyle indications. Its lead product is an injectable treatment to achieve local, selective fat tissue reduction (pharmaceutical lipoplasty). Using FDA registered drugs proven safe and effective in other indications, its product targets and stimulates natural fat metabolism and achieves non-ablative, non-surgical fat tissue reduction in specific locations.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $25M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  43. two men using computers


  44. Arena Pharmaceuticals ($10M to $50M)

    Clinical-stage biotech focused on cardiovascular, central nervous system, inflammatory and metabolic diseases. Their leading drug candidate is lorcaserin hydrochloride, which recently received positive data from a clinical trial. They are headquartered in San Diego, CA.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $56M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  45. people standiunmg


  46. Abwiz Bio (Less than $1M)

    It provide researchers world-wide with top-quality monoclonal antibodies through novel immunization and unique cloning methods using phage display technology.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in September, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  47. people sitting beside rectangular brown table with laptops


  48. Viriom ($10M to $50M)

    Viriom Inc. is a development and commercial stage biotech company developing novel and affordable medicines against life threatening infections such as HIV and HBV. The company has an exclusive worldwide license to its phase 3 and commercial stage lead compounds (Elpida/elsulfavirine and VM1500A) from Hoffmann-La Roche and has developed proprietary drug candidates VM2500, VM3500 LAI formulations and combinations with cell, vaccine and antibody drugs for treatment, prophylaxis and cure of HIV. Viriom makes a breakthrough in treating, preventing and curing HIV and chronic HBV infections worldwide.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $12.5M raised in December, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  49. man in black jacket sitting on chair


  50. Neuropore Therapies ($1M to $10M)

    Neuropore Therapies is a pharmaceutical company located in San Diego, CA committed to the discovery and development of disease-modifying treatments for neurodegenerative disorders, including Parkinson’s disease and Alzheimer’s disease. They are located on Road to the Cure in San Diego, CA.Their approach is based on the fundamental concept that the pathological accumulation of misfolded and aggregated neurotoxic proteins is the underlying basis of these disorders. Their therapeutic candidates directly target these proteins and restore cellular autophagy mechanisms to degrade and dispose of these neurotoxic proteins.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.5M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  51. architectural photo of buildings during daytime


  52. BioIntervene ($1M to $10M)

    BioIntervene, Inc. is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene’s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $30M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  53. people sitting on chairs near tables during daytime


  54. Sorrento Therapeutics ($10M to $50M)

    Sorrento is a clinical-stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical-stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and clinical-stage oncolytic virus (“Sephrevir”).

    • $10M to $50M annual revenues
    • 251-500 employees
    • $1.9M raised in October, 2013
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  55. tennis table in room


  56. Biosortia Pharmaceuticals ($1M to $10M)

    Biosortia works on new drugs from deep access to the chemistry of the microbiome for immuno-oncology and immunological therapeutics. It has the only capability in the world to obtain the long-sought, but previously unobtainable drug-like molecules directly from the microbiome. The company was founded in 2012 and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.5M raised in August, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  57. grayscale photo of people in room


  58. ACADIA Pharmaceuticals ($50M to $100M)

    ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinson's disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimer's disease psychosis, for which it is initiating a Phase II feasibility study.

    • $50M to $100M annual revenues
    • 101-250 employees
    • $86.4M raised in January, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  59. Adamis Pharmaceuticals ($1M to $10M)

    Adamis Pharmaceuticals Corporation (ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $51.7M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. brown wooden table and chairs


  61. BioBlocks ($50M to $100M)

    BioBlocks is a collaborative medicinal chemistry research organization focused on drug discovery from initial lead discovery through identification of development candidates. They believe that collaboration empowers scientists to achieve more than any single entity or individual could alone. They join forces with their clients to discover compounds qualified for advancement to phase two clinical trials.

    • $50M to $100M annual revenues
    • 1-10 employees
    • $0.1M raised in August, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. people having meeting on rectangular brown table


  63. Nanome (Less than $1M)

    Nanome is a virtual reality software company that offers a collaborative XR software platform for molecular design. The platform accelerates existing computational workflows at the molecular scale and unlocks more scientists to leverage powerful molecular computations + AI. Nanome has worked largely on projects with companies in the food and beverage industry, as well as another to develop more sustainable batteries. The San Diego, California-based company was launched in 2015 by Edgardo Leija, Samuel Hessenauer, Keita Funakawa, and Steven McCloskey.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3M raised in February, 2021
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. men using computers


  65. Escient Pharmaceuticals ($1M to $10M)

    Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required for treatment of serious, unserved medical needs across a broad range of therapeutic indications.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $77.5M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. people using desktop computer inside office


  67. Prometheus Biosciences ($10M to $50M)

    Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.

    • $10M to $50M annual revenues
    • 501-1000 employees
    • $130M raised in November, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. group of people sitting beside rectangular wooden table with laptops


  69. Kinnate Biopharma (Less than $1M)

    Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

    • Less than $1M annual revenues
    • 51-100 employees
    • $98M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  70. man and woman sitting at table


  71. Sorrento Therapeutics ($1M to $10M)

    Sorrento Therapeutics is a development-stage biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento’s late stage pipeline include Cynviloq™ (paclitaxel in polymeric micelle formulation) currently in a registrational bio-equivalent study versus albumin-bound paclitaxel; and Resiniferatoxin (RTX),which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. Sorrento has one of the industry’s most diverse antibody (G-MAB®) library comprised of high-quality, fully human antibodies with a diversity of more than ten trillion (>10^16). Along with its' proprietary conjugation chemistries and novel toxins, Sorrento has all in-house capabilities to generate and develop a new generation of homogenous ADCs with well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to improved ADC stability and pharmacokinetics while reducing off-target effects compared to existing ADCs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $25M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  72. three women sitting around table using laptops


  73. Allylix ($10M to $50M)

    Allylix, Inc., an early stage biotechnology company, develops terpene products and their derivatives for the flavor and fragrance, food ingredient, pharmaceutical, agricultural, and biofuel markets. Its products comprise nootkatone, which is a grapefruit flavor that is used in fruit juices and citrus flavored sodas. The company also develops sesquiterpenes that are part of aroma chemical segment of the flavor and fragrance market; and production platforms for pharmaceutical, nutraceutical, and agricultural markets. Allylix, Inc. was founded in 2002 and is based in San Diego, California with research and development laboratories in Lexington, Kentucky.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $18.2M raised in March, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  74. photo of industrial machines near table


  75. Peptide Logic (Less than $1M)

    Peptide Logic is a biopharmaceutical company that combines the advantages of synthetic peptides and recombinant antibodies to create transformative peptide-antibody conjugates (PACs) for pain and other selected therapeutic areas. To create the peptide-based drugs of the future, Peptide Logic is building the most comprehensive and versatile peptide technology platform through in-licensing, partnerships, and internal development. It is also developing multi-product pipelines of first-in-class peptide-based drugs in pain and other selected therapeutic areas.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.9M raised in August, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  76. people sitting in front of computer monitors


  77. Lumena Pharmaceuticals ($10M to $50M)

    Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

    • $10M to $50M annual revenues
    • 5001-10000 employees
    • $45M raised in March, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  78. man in gray sweatshirt sitting on chair in front of iMac


  79. PROTEIN LOUNGE (Less than $1M)

    Protein Lounge is a gene/protein centric web portal that offers databases covering major model organisms, and molecular and bioinformatics research tools useful for research and teaching. We have developed tools to facilitate understanding cellular networks, protein interactions involved in cell signaling, mechanisms of cell survival and apoptosis leading to development or identification of drug candidates against a variety of diseases. Protein Lounge has constructed the first complete siRNA target database, a complete Peptide-Antigen target database and a Kinase-Phosphate database, just to name a few. We offer the largest online database of illustrated signal transduction pathways, which are interconnected to an extensive protein database and gene/protein analysis tools. We have web based software that enables biologists to draw creative pathways and biological graphics for digital and print media. We also have custom animations for pharmaceutical and biotech companies. Protein Lounge will work with you directly to create a custom animation that is tailored specifically to your target audience and marketing needs. To ensure the highest quality, we have a large team of professional 3D graphic designers working in tandem with our scientific advisers. Specialties siRNA Database, Biological Animation, Biological Pathway Builder Tool, Protein Hydroplotter, Clone Easy Tool, GPCR Database, Kinase-Phosphate database, Transcription Factor Database, Protein Vision tool-3D Protein structure, DNA and Protein Sequence Comparison Tool

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in June, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  80. rectangular brown wooden table


  81. Zogenix (Less than $1M)

    At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DoseProâ„¢, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain.

    • Less than $1M annual revenues
    • 51-100 employees
    • $15M raised in July, 2010
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  82. people sitting on black chairs


  83. aTyr Pharma ($10M to $50M)

    aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $45M raised in August, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  84. selective focus photography of desk lamp on table


  85. Ambra BioScience LLC - Lovidia (Less than $1M)

    Ambra BioScience LLC - Lovidia is a biotechnology company based in San Diego, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.1M raised in December, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  86. Genoa Pharmaceuticals ($1M to $10M)

    Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $62M raised in May, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  87. two women sitting beside table using MacBooks


  88. Zavante Therapeutics ($10M to $50M)

    Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $10M raised in September, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  89. rectangular brown wooden table with chair lot inside building


  90. Mirum Pharmaceuticals ($50M to $100M)

    Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

    • $50M to $100M annual revenues
    • 11-50 employees
    • $10M raised in December, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  91. grey wooden table and black leather rolling chairs


  92. PharmAkea Therapeutics ($1M to $10M)

    PharmAkea is a biopharmaceutical company based in San Diego, CA. The company is developing high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $10M raised in October, 2013
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  93. brown and white table and chairs


  94. Mast Therapeutics (Less than $1M)

    (NYSE MKT: MSTX) We are a San Diego-based biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions.

    • Less than $1M annual revenues
    • 11-50 employees
    • $8M raised in February, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  95. rolling armchair beside table


  96. ReVision Therapeutics (Less than $1M)

    ReVision Therapeutics, Inc. develops drugs for the treatment of age-related macular degeneration diseases. Its product includes Fenretinide, an oral medication that reduces the accumulation of A2E in the retina, and slows down the growth of atrophic lesions, which precedes vision loss. The company was founded in 2010 and is based in San Diego, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.5M raised in December, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  97. men sitting of chair inside room


  98. Ligand Pharmaceuticals ($10M to $50M)

    Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $650M raised in May, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  99. people sitting and using laptops


  100. Longboard Pharmaceuticals ($10M to $50M)

    Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $56M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  101. two men using computers


  102. HUYA Bioscience ($1M to $10M)

    HUYA Bioscience enables and accelerates the global development of novel biopharmaceutical product opportunities. It identifies and licenses pre-clinical and clinical-stage compounds, then leverages and extends the research efforts of its partners and also provides a bridge into the international development process and global biopharma market while lowering risk, providing partner companies with an ensured and continuous source of compounds for the future. HUYA Bioscience was founded in 2004 and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $48M raised in April, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  103. people standiunmg


  104. Engrail Therapeutics ($10M to $50M)

    Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $32M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  105. people sitting beside rectangular brown table with laptops


  106. Dauntless Pharmaceuticals ($1M to $10M)

    Dauntless Pharmaceuticals is a therapeutics company that focuses on the development of drugs. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share an interest in all company assets. It was founded in 2015 and headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $25M raised in February, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  107. man in black jacket sitting on chair


  108. Sevion Therapeutics ($50M to $100M)

    Sevion is a biopharmaceutical company which discovers, develops and acquires innovative product candidates for the treatment of cancer and immunological diseases. The Company is advancing a pipeline of proprietary and partnered product candidates that leverages its unique antibody technology platforms. The Company’s antibody pipeline is being developed from technology that allows for the discovery of innovative biologic therapies to previously inaccessible targets, such as multispanning membrane proteins and ion channels that play an important role in multiple diseases. The Company also developed the first protein nanocage system allowing delivery of nucleic acids and other payloads to target cells.

    • $50M to $100M annual revenues
    • 11-50 employees
    • $3M raised in May, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  109. architectural photo of buildings during daytime


  110. Marijuana Company Of America (Less than $1M)

    Marijuana Company Of America is a community and lifestyle company based in San Diego, California.

    • Less than $1M annual revenues
    • 101-250 employees
    • $10M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  111. people sitting on chairs near tables during daytime


  112. Onchilles Pharma ($10M to $50M)

    Onchilles Pharma is a biotechnology company developing first-in-class biologics therapies for the treatment of cancer. The company's drug selectively targets cancer cells and is non-toxic to normal cells and tissues, helping medical professionals treat cancer patients efficiently. It was founded in 2017 and is headquartered in San Diego, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3.6M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  113. tennis table in room


  114. Mapp Biopharmaceutical ($1M to $10M)

    Mapp Biopharmaceutical was created to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company has been developing an Ebola therapy for more than a decade and has been working with the United States and Canadian governments to develop this therapy. Mapp Biopharmaceutical was founded in 2003 by Kevin Whaley and Larry Zeitlin. It is headquartered in San Diego, C.A.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $16.5M raised in June, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  115. grayscale photo of people in room


  116. MEI Pharma ($1M to $10M)

    MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $75M raised in May, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  117. MabVax Therapeutics ($1M to $10M)

    MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $11M raised in July, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. brown wooden table and chairs


  119. Genelux ($1M to $10M)

    Genelux Corporation is a privately-held, clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccina virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $20M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. people having meeting on rectangular brown table


  121. PvP Biologics ($1M to $10M)

    PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $35M raised in January, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  122. men using computers


  123. MedImpact Healthcare Systems ($10M to $50M)

    Founded in 1989 and headquartered in San Diego, Calif., MedImpact Healthcare Systems, Inc. provides PBM services to the Commercial MCO, Medicare, Medicaid, Self-insured, State/Local Government, 340B, and Discount/Retail Pharmacy Loyalty Card market segments. MedImpact manages pharmacy benefits for more than 47 million lives around the globe.

    • $10M to $50M annual revenues
    • 5001-10000 employees
    • $1.4M raised in September, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  124. people using desktop computer inside office


  125. Camino Pharma (Less than $1M)

    Camino Pharma is a San Diego-based startup company focused on discovering and developing first-in-class therapies for patients suffering from cancer and CNS disorders. They target signaling proteins based on emerging biological concepts and discover novel mechanisms for modulating these targets with small molecule drugs. Their leadership team has proven expertise in the relevant target biology, as well as extensive experience in drug discovery and development.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.9M raised in June, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  126. group of people sitting beside rectangular wooden table with laptops


  127. AnaBios ($1M to $10M)

    AnaBios specializes in enabling human-focused drug discovery. As a CRO, AnaBios provides products and services for every stage of drug discovery. Through proprietary technology based on the use of human donor organs and tissues, it studies ex vivo human responses to drugs and further investigate the molecular and functional basis of relevant human physiology. Its research focuses primarily on the areas of high, unmet medical need, including cardiac disease and safety, pain, PKD kidney disease, and neurodegeneration. In partnership with Fortune 500 pharmaceutical companies, contract research organizations, and universities, the company's mission is to develop therapeutic advancements to help patients live longer, healthier, and more productive lives.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.1M raised in December, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  128. man and woman sitting at table


  129. ARS Pharmaceuticals ($1M to $10M)

    ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $8M raised in September, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  130. three women sitting around table using laptops


  131. Plex Pharmaceuticals ($1M to $10M)

    Plex's mission is to accelerate seminal academic discoveries into safe and effective treatments for unmet and under-served medical needs with a focus on neurodegenerative disorders.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.6M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  132. photo of industrial machines near table


  133. Otonomy (Less than $1M)

    Otonomy was founded in 2008 by Avalon Ventures and experts in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus. The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes and from these, three product candidates have been advanced into development.

    • Less than $1M annual revenues
    • 51-100 employees
    • $49M raised in April, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  134. people sitting in front of computer monitors


  135. Ocunexus Therapeutics ($1M to $10M)

    Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications. Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $9.1M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  136. man in gray sweatshirt sitting on chair in front of iMac


  137. Librede (Less than $1M)

    Librede Inc. is a company that has a mission to improve the quality of life through innovated sustainable technologies. Librede focuses on the creation of platform technologies that enable the creation of new therapeutics; they use biology to build devices and manufacture molecules. They have developed the world’s first biosynthetic production platform that is targeting the endocannabinoid system.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.5M raised in February, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  138. rectangular brown wooden table


  139. Receptos ($1M to $10M)

    Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $30M raised in March, 2013
    • 7 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  140. people sitting on black chairs


  141. MediciNova ($1M to $10M)

    MediciNova is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers

    • $1M to $10M annual revenues
    • 11-50 employees
    • $20M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  142. selective focus photography of desk lamp on table


  143. Jaleva Pharmaceuticals ($1M to $10M)

    Jaleva Pharmaceuticals, LLC, a specialty pharmaceutical company, engages in the research and development of dermal drug delivery system that promotes transmucosal and topical delivery of medications for central nervous system markets. Its products include Mast-R-Prep, a chlorhexidine-based surgical skin prep product; and Stayzon, an antibiotic surgical adhesive. The company’s formulations are designed to provide delivery of alprazolam for anxiety; ondansetron for nausea; sumitriptan for migraines; fentanyl for pain; and nicotine as an aid to smoking cessation. Jaleva Pharmaceuticals, LLC was founded in 1999 and is based in San Diego, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.5M raised in May, 2011
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  144. Reneo Pharmaceuticals ($1M to $10M)

    Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $95M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  145. two women sitting beside table using MacBooks


  146. Elgia Therapeutics ($10M to $50M)

    Elgia Therapeutics is a biotechnology company that specializes in novel approaches for the treatment of chronic inflammatory and fibrotic diseases. It specializes in the fields of healthcare, therapeutics, pharmaceutical, and medicine. It was founded in 2019 and headquartered in San Diego, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.3M raised in April, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  147. rectangular brown wooden table with chair lot inside building


  148. RayzeBio ($10M to $50M)

    RayzeBio is focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. As the emerging leader in radiopharmaceuticals, RayzeBio is developing an innovative robust pipeline against validated oncology drug targets to deliver radioisotopes that emit alpha particles such as Actinium-225.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $105M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  149. grey wooden table and black leather rolling chairs


  150. Sonexa Therapeutics (Less than $1M)

    Sonexa Therapeutics, Inc., a pharmaceutical company, engages in the development of therapeutics drugs for the treatment of Alzheimer's disease and related disorders. It develops ST101, a small and orally active molecule compound that penetrates the blood-brain-barrier. The company was incorporated in 2007 and is based in San Diego, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $2M raised in August, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  151. brown and white table and chairs


  152. LPATH ($50M to $100M)

    Lpath, Inc. is the category leader in the discovery and development of monoclonal antibodies that target (neutralize) bioactive lipids. The study of lipids (called lipidomics) is an emerging field of research that has already identified dozens of bioactive lipids that contribute to disease, with the promise of hundreds more as funding in the area continues to accelerate. Once a disease-causing lipid is identified, however, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2:tm: platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.

    • $50M to $100M annual revenues
    • 11-50 employees
    • $12.5M raised in October, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  153. rolling armchair beside table


  154. NantKwest (Less than $1M)

    NantKwest is a clinical-stage immunotherapy company focused on harnessing the immune system to treat disease. It is a biotechnology company, engages in developing immunotherapeutic agents for various clinical conditions in the United States. The company’s product candidates include activated natural killer candidates for the treatment of virally-induced cancers, such as human papilloma virus-induced cervical, and head and neck cancers; ebola; and serious viral, fungal, and bacterial infections, as well as that is in Phase II clinical trials for the treatment of polyoma virus-induced merkel cell carcinoma.

    • Less than $1M annual revenues
    • 51-100 employees
    • $39M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  155. men sitting of chair inside room


  156. Ambit Biosciences ($10M to $50M)

    Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $50M raised in November, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  157. people sitting and using laptops


  158. Turning Point Therapeutics ($50M to $100M)

    Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

    • $50M to $100M annual revenues
    • 51-100 employees
    • $373.8M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  159. two men using computers


  160. Metacrine ($10M to $50M)

    Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $50M raised in September, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  161. people standiunmg


  162. Tioga Pharmaceuticals (Less than $1M)

    Tioga Pharmaceuticals, Inc. develops therapies for the treatment of gastrointestinal diseases. Its product includes asimadoline, an orally administered small molecule therapeutic for the treatment of irritable bowel syndrome and functional dyspepsia. The company was founded in 2005 and is based in San Diego, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $10M raised in April, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  163. people sitting beside rectangular brown table with laptops


  164. Molecular Stethoscope ($1M to $10M)

    Tissue-specific cell-free circulating RNA is a newly developed area for molecular diagnosis. Based on this powerful non-invasive approach, Molecular Stethoscope aims to transform healthcare by providing early insight into a patient’s healthy versus disease state.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $8.2M raised in January, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  165. man in black jacket sitting on chair


  166. Cosmederm Bioscience (Less than $1M)

    Cosmederm Bioscience is a specialty pharmaceutical company focusing on the development of uniquely potent topical dermatological products. We are committed to being a trusted leader in the areas of anti-aging, acne and other inflammatory skin conditions. Unlike some other companies' products, ours are the result of years of laboratory research and millions of dollars in clinical and developmental costs. The efficacy of our products is proven, and our technology is supported by clinical studies published in peer reviewed medical journals and textbooks.

    • Less than $1M annual revenues
    • 11-50 employees
    • $50M raised in October, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  167. architectural photo of buildings during daytime


  168. Mirati Therapeutics (Less than $1M)

    Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

    • Less than $1M annual revenues
    • 51-100 employees
    • $234.3M raised in June, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  169. people sitting on chairs near tables during daytime


  170. Selexagen Therapeutics ($1M to $10M)

    Selexagen Therapeutics, Inc. operates as a pharmaceutical company and develops targeted therapies for cancer. The company was incorporated in 2008 and is based in San Diego, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.6M raised in August, 2011
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  171. tennis table in room


  172. Adastra Pharmaceuticals ($1M to $10M)

    Adastra Pharmaceuticals is a private clinical-stage oncology company that provides responsible solutions to advance patient care in oncology. It develops pharmaceutical proprietary medicines for the treatment of various cancers. The company's medicines include an oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin-dependent kinases equipotently, enabling healthcare professional to ensure better survival of their patients. Adastra Pharmaceuticals was founded in 2005 and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $3.3M raised in November, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  173. grayscale photo of people in room


  174. Viracta Therapeutics ($10M to $50M)

    Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $40M raised in November, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  175. Crinetics Pharmaceuticals (Less than $1M)

    Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

    • Less than $1M annual revenues
    • 11-50 employees
    • $3.2M raised in June, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  176. brown wooden table and chairs


  177. Neurana Pharmaceuticals ($1M to $10M)

    Neurana Pharmaceuticals is a biotechnology company that is currently developing a novel treatment for acute muscle spasms. The company was founded in 2013 and headquartered in California, United States.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $60M raised in May, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  178. people having meeting on rectangular brown table


  179. Ensysce Biosciences (Less than $1M)

    We’re a biotech company committed to stemming the prescription drug abuse epidemic. Our proprietary prodrug technologies: abuse resistant TAAP™ and overdose resistant MPAR™ are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse. In addition to working with all known prescription opioid drugs, our abuse-resistant drug technologies TAAP™ and MPAR™ have broad potential across a variety of other drugs with the possibility of abuse. For example, we currently have multiple TAAP™ products in the pipeline including one for ADHD.

    • Less than $1M annual revenues
    • 11-50 employees
    • $60M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  180. men using computers


  181. Ansun BioPharma ($1M to $10M)

    Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of unique host-directed anti-viral. The company is committed to developing safe and effective immuno-biologic therapies to treat the most vulnerable patients. Its founders were ingenious virologists and molecular biologists who realized that targeting a virus is difficult due to the virus’s ability to mutate and avoid the treatment. This ability to mutate also enables the virus to evade vaccines. So instead of trying to hit a moving target, they developed an innovative new approach to fight respiratory viruses: they targeted the host instead of the virus. The company was founded in 2003 and is headquartered in San Diego, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $100M raised in October, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  182. people using desktop computer inside office


  183. Aspen Neuroscience (Less than $1M)

    Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It develops enabling technologies for patient-specific induced pluripotent stem cell-based therapies.

    • Less than $1M annual revenues
    • 11-50 employees
    • $70M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  184. group of people sitting beside rectangular wooden table with laptops


  185. La jolla Pharmaceutical ($1M to $10M)

    La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $17.8M raised in October, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  186. man and woman sitting at table


  187. Idun Pharmaceuticals ($10M to $50M)

    IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $1.1M raised in July, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  188. three women sitting around table using laptops


  189. Pipeline Therapeutics ($1M to $10M)

    Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $80M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  190. photo of industrial machines near table


  191. Meritage Pharma ($10M to $50M)

    Meritage Pharma, Inc. develops prescription products for the treatment of gastrointestinal and atopic diseases. It offers budesonide, an active pharmaceutical ingredient and a glucocorticoid steroid for products that treat pediatric asthma, allergic rhinitis, and Crohn’s disease; and oral budesonide suspension, an oral formulation of budesonide for the potential treatment of adolescents and young adults with eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract. Meritage Pharma, Inc. was founded in 2008 and is based in San Diego, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $6.5M raised in November, 2011
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  192. people sitting in front of computer monitors